FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1274 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR New breast and lung cancer treatments approved in Scotland January 19, 2022 Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 New drug available for rare thyroid cancer on NHS in England October 1, 2021 FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions December 16, 2021 Load more HOT NEWS Precision drug slows progression of advanced breast cancer Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... FDA Approves First Immunotherapy Treatment For Breast Cancer A radical project: video game design meets cancer research
